Dr. Fengwei Tan 谭锋维
Chief Physician
Department of Thoracic Surgery, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of chest tumors, including lung cancer, esophageal cancer, cardia cancer, mediastinal tumors, and lung metastases. Specializes in the diagnosis and minimally invasive surgical treatment of pulmonary nodules.
Dr. Tan holds dual doctoral degrees in clinical medicine and molecular biology from Peking Union Medical College. Dr. Tan completed advanced training at MD Anderson Cancer Center and UCLA Medical Center in the United States. Dr. Tan has led or participated in seven national-level research projects and published more than 10 academic papers.
Professional roles
- Secretary-General, Young Committee of Thoracic Surgery Branch, Chinese Medical Doctor Association
- Young Committee Member, Esophageal Cancer Professional Committee, China Anti-Cancer Association
- Young Committee Member, Thoracic Surgery Branch, Beijing Medical Association
- Reviewer, Chinese Journal of Oncology
Name order: in Chinese the family name comes first (Tan Fengwei). Papers usually list the name as Fengwei Tan or Tan F.
Selected publications
160 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Ann Thorac Surg, 2026 (senior author): Surgical and Survival Benefits of Neoadjuvant Targeted Therapy vs Chemoimmunotherapy in Lung Adenocarcinoma: A Dual-Center Research. PubMed 41651053
- Thorac Cancer, 2026 (senior author): Radiological, Molecular, and Pathological Factors Unite: A Model for Predicting Recurrence-Free Survival in Pathological Stage I Lung Adenocarcinoma. PubMed 42023991
- J Natl Cancer Cent, 2026 (first author): Long-term outcomes and clinical features of stage III non-small-cell lung cancer harboring ALK rearrangements: a multicenter retrospective study of 176 patients. PubMed 42007220
- BMC Cancer, 2026 (senior author): Integrated analysis reveals GSTA1 as a prognostic biomarker in stage I lung adenocarcinoma. PubMed 41664068
- Int J Surg, 2026 (senior author): A retrospective cross-sectional analysis of global esophageal cancer and gastroesophageal reflux disease burden: temporal trends, regional disparities, and epidemiologic associations. PubMed 41231619
- J Adv Res, 2026 (senior author): Lipidomic signatures as predictive biomarkers for early-onset lung cancer: Identification and development of a risk prediction model. PubMed 40180245
- Front Immunol, 2025 (senior author): Recent advances in biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer. PubMed 40406096
- Thorac Cancer, 2025 (senior author): Reassessment of the Prognostic Implication of Ground-Glass Opacity: An Investigation Into Hypermetabolic Clinical Stage IA Lung Adenocarcinoma. PubMed 39904725
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion